Cardiovascular risk evaluation through heart rate variability analysis in psoriatic patients before and after 24 weeks of etanercept therapy: Prospective study

OBJECTIVE: To assess the influence of etanercept, an anti-tumour necrosis factor (TNF)-α agent, on autonomic cardiovascular regulation in young patients with moderate-to-severe psoriasis without cardiovascular risk factors. METHODS: Patients with psoriasis underwent 5-min electrocardiogram (ECG) rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Potenza, Concetta, Raimondi, Gianfranco, Pampena, Riccardo, Proietti, Ilaria, Viola, Giorgio La, Bernardini, Nicoletta, Tolino, Ersilia, Zuber, Sara, Balduzzi, Veronica, Scordamaglia, Beatrice, Skroza, Nevena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Immuno-Mediated Diseases and Treatment Immunogenicity
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536535/
https://www.ncbi.nlm.nih.gov/pubmed/27683138
http://dx.doi.org/10.1177/0300060515593242
_version_ 1783254027104944128
author Potenza, Concetta
Raimondi, Gianfranco
Pampena, Riccardo
Proietti, Ilaria
Viola, Giorgio La
Bernardini, Nicoletta
Tolino, Ersilia
Zuber, Sara
Balduzzi, Veronica
Scordamaglia, Beatrice
Skroza, Nevena
author_facet Potenza, Concetta
Raimondi, Gianfranco
Pampena, Riccardo
Proietti, Ilaria
Viola, Giorgio La
Bernardini, Nicoletta
Tolino, Ersilia
Zuber, Sara
Balduzzi, Veronica
Scordamaglia, Beatrice
Skroza, Nevena
author_sort Potenza, Concetta
collection PubMed
description OBJECTIVE: To assess the influence of etanercept, an anti-tumour necrosis factor (TNF)-α agent, on autonomic cardiovascular regulation in young patients with moderate-to-severe psoriasis without cardiovascular risk factors. METHODS: Patients with psoriasis underwent 5-min electrocardiogram (ECG) recordings before and after 24 weeks of etanercept therapy. Linear heart rate variability (HRV) analysis was performed. RESULTS: The study recruited 19 patients. Frequency-domain analysis showed a significant decrease in oscillatory components attributable to sympathetic activity (LF%) and a significant decrease in low frequency/high frequency (LF/HF) ratio following etanercept therapy. CONCLUSION: Treatment with etanercept in patients with moderate-to-severe psoriasis could affect cardiovascular autonomic regulation, and subsequently reduce cardiovascular risk.
format Online
Article
Text
id pubmed-5536535
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-55365352017-10-03 Cardiovascular risk evaluation through heart rate variability analysis in psoriatic patients before and after 24 weeks of etanercept therapy: Prospective study Potenza, Concetta Raimondi, Gianfranco Pampena, Riccardo Proietti, Ilaria Viola, Giorgio La Bernardini, Nicoletta Tolino, Ersilia Zuber, Sara Balduzzi, Veronica Scordamaglia, Beatrice Skroza, Nevena J Int Med Res Immuno-Mediated Diseases and Treatment Immunogenicity OBJECTIVE: To assess the influence of etanercept, an anti-tumour necrosis factor (TNF)-α agent, on autonomic cardiovascular regulation in young patients with moderate-to-severe psoriasis without cardiovascular risk factors. METHODS: Patients with psoriasis underwent 5-min electrocardiogram (ECG) recordings before and after 24 weeks of etanercept therapy. Linear heart rate variability (HRV) analysis was performed. RESULTS: The study recruited 19 patients. Frequency-domain analysis showed a significant decrease in oscillatory components attributable to sympathetic activity (LF%) and a significant decrease in low frequency/high frequency (LF/HF) ratio following etanercept therapy. CONCLUSION: Treatment with etanercept in patients with moderate-to-severe psoriasis could affect cardiovascular autonomic regulation, and subsequently reduce cardiovascular risk. SAGE Publications 2016-09-28 2016-09 /pmc/articles/PMC5536535/ /pubmed/27683138 http://dx.doi.org/10.1177/0300060515593242 Text en © The Author(s) 2016 http://creativecommons.org/licenses/by-nc/3.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Immuno-Mediated Diseases and Treatment Immunogenicity
Potenza, Concetta
Raimondi, Gianfranco
Pampena, Riccardo
Proietti, Ilaria
Viola, Giorgio La
Bernardini, Nicoletta
Tolino, Ersilia
Zuber, Sara
Balduzzi, Veronica
Scordamaglia, Beatrice
Skroza, Nevena
Cardiovascular risk evaluation through heart rate variability analysis in psoriatic patients before and after 24 weeks of etanercept therapy: Prospective study
title Cardiovascular risk evaluation through heart rate variability analysis in psoriatic patients before and after 24 weeks of etanercept therapy: Prospective study
title_full Cardiovascular risk evaluation through heart rate variability analysis in psoriatic patients before and after 24 weeks of etanercept therapy: Prospective study
title_fullStr Cardiovascular risk evaluation through heart rate variability analysis in psoriatic patients before and after 24 weeks of etanercept therapy: Prospective study
title_full_unstemmed Cardiovascular risk evaluation through heart rate variability analysis in psoriatic patients before and after 24 weeks of etanercept therapy: Prospective study
title_short Cardiovascular risk evaluation through heart rate variability analysis in psoriatic patients before and after 24 weeks of etanercept therapy: Prospective study
title_sort cardiovascular risk evaluation through heart rate variability analysis in psoriatic patients before and after 24 weeks of etanercept therapy: prospective study
topic Immuno-Mediated Diseases and Treatment Immunogenicity
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536535/
https://www.ncbi.nlm.nih.gov/pubmed/27683138
http://dx.doi.org/10.1177/0300060515593242
work_keys_str_mv AT potenzaconcetta cardiovascularriskevaluationthroughheartratevariabilityanalysisinpsoriaticpatientsbeforeandafter24weeksofetanercepttherapyprospectivestudy
AT raimondigianfranco cardiovascularriskevaluationthroughheartratevariabilityanalysisinpsoriaticpatientsbeforeandafter24weeksofetanercepttherapyprospectivestudy
AT pampenariccardo cardiovascularriskevaluationthroughheartratevariabilityanalysisinpsoriaticpatientsbeforeandafter24weeksofetanercepttherapyprospectivestudy
AT proiettiilaria cardiovascularriskevaluationthroughheartratevariabilityanalysisinpsoriaticpatientsbeforeandafter24weeksofetanercepttherapyprospectivestudy
AT violagiorgiola cardiovascularriskevaluationthroughheartratevariabilityanalysisinpsoriaticpatientsbeforeandafter24weeksofetanercepttherapyprospectivestudy
AT bernardininicoletta cardiovascularriskevaluationthroughheartratevariabilityanalysisinpsoriaticpatientsbeforeandafter24weeksofetanercepttherapyprospectivestudy
AT tolinoersilia cardiovascularriskevaluationthroughheartratevariabilityanalysisinpsoriaticpatientsbeforeandafter24weeksofetanercepttherapyprospectivestudy
AT zubersara cardiovascularriskevaluationthroughheartratevariabilityanalysisinpsoriaticpatientsbeforeandafter24weeksofetanercepttherapyprospectivestudy
AT balduzziveronica cardiovascularriskevaluationthroughheartratevariabilityanalysisinpsoriaticpatientsbeforeandafter24weeksofetanercepttherapyprospectivestudy
AT scordamagliabeatrice cardiovascularriskevaluationthroughheartratevariabilityanalysisinpsoriaticpatientsbeforeandafter24weeksofetanercepttherapyprospectivestudy
AT skrozanevena cardiovascularriskevaluationthroughheartratevariabilityanalysisinpsoriaticpatientsbeforeandafter24weeksofetanercepttherapyprospectivestudy

Ejemplares similares